American Association for Cancer Research 2017 Annual Meeting

April 20, 2017

Ignyta’s RXDX-106 Works with Immune Checkpoint Inhibitors to Kill Tumors, Study Shows

News

Ignyta’s RXDX-106 can restore the body’s immune-system response against several types of tumors and work with immune checkpoint inhibitors to kill tumor cells, according to a company presentation at the American Association ... Read more

April 11, 2017April 11, 2017

SY-1425 May Work in Combo with Approved Therapies in Leukemia Patients, Others with Blood Disorders

News

Preclinical data on SY-1425, Syros Pharmaceuticals’ selective retinoic acid receptor alpha (RARα) agonist, suggest this is a promising treatment to be used in combination with Vidaza (azaciditine), a standard of ... Read more